Keep up to date with every new upload!

Join free & follow MoneyLife with Chuck Jaffe Dai
Dennis: Exelixis is poised to move on two cancer drugs.

Dennis: Exelixis is poised to move on two cancer drugs.

Kyle Dennis of BiotechBreakouts.com says that Exelixis Inc. (EXEL) has the fundamental and technical support to make a strong move ahead of expected approval of two cancer drugs in January and February. Also, Scott Sacknoff of SerenityShares ETFs talks social investments, Kyle Guske of New Constructs puts a software company in the Danger Zone, and Jack Bowers of the Fidelity Monitor and Insight newsletter has the Market Call.

Comments